La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Firebrick Pharma Gestione
Gestione criteri di controllo 3/4
Firebrick Pharma's CEO is Peter Molloy, appointed in Apr 2012, has a tenure of 12.33 years. total yearly compensation is A$351.30K, comprised of 80.7% salary and 19.3% bonuses, including company stock and options. directly owns 16.05% of the company’s shares, worth A$1.76M. The average tenure of the management team and the board of directors is 3.7 years and 8 years respectively.
Informazioni chiave
Peter Molloy
Amministratore delegato
AU$351.3k
Compenso totale
Percentuale dello stipendio del CEO | 80.7% |
Mandato del CEO | 12.3yrs |
Proprietà del CEO | 16.1% |
Durata media del management | 3.7yrs |
Durata media del Consiglio di amministrazione | 8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Here's Why We're Watching Firebrick Pharma's (ASX:FRE) Cash Burn Situation
Aug 14We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
May 02We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
Dec 14Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth
Aug 30Analisi delle retribuzioni degli amministratori delegati
Data | Compenso totale | Stipendio | Guadagni aziendali |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -AU$5m |
Sep 30 2023 | n/a | n/a | -AU$6m |
Jun 30 2023 | AU$351k | AU$284k | -AU$7m |
Mar 31 2023 | n/a | n/a | -AU$6m |
Dec 31 2022 | n/a | n/a | -AU$5m |
Sep 30 2022 | n/a | n/a | -AU$5m |
Jun 30 2022 | AU$324k | AU$252k | -AU$4m |
Mar 31 2022 | n/a | n/a | -AU$3m |
Dec 31 2021 | n/a | n/a | -AU$3m |
Sep 30 2021 | n/a | n/a | -AU$3m |
Jun 30 2021 | AU$140k | AU$140k | -AU$2m |
Compensazione vs Mercato: Peter's total compensation ($USD235.99K) is about average for companies of similar size in the Australian market ($USD299.11K).
Compensazione vs guadagni: Peter's compensation has increased whilst the company is unprofitable.
AMMINISTRATORE DELEGATO
Peter Molloy (70 yo)
12.3yrs
Mandato
AU$351,298
Compensazione
Dr. Peter Laurence Molloy, BSc, MBA, FAICD is the Founder, Executive Chairman and Chief Executive Officer of Firebrick Pharma Limited since April 12, 2012. He served as Managing Director and Chief Executiv...
Gruppo dirigente
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
Founder | 12.3yrs | AU$351.30k | 16.05% A$ 1.8m | |
Founder | 12.3yrs | AU$290.56k | 15.8% A$ 1.7m | |
Chief Financial Officer | 1.7yrs | Nessun dato | Nessun dato | |
Chief Scientific Officer | no data | Nessun dato | 0.51% A$ 56.0k | |
Chief Medical Officer | no data | Nessun dato | Nessun dato | |
Head of Regulatory Affairs | 2.7yrs | Nessun dato | Nessun dato | |
Company Secretary | 3.7yrs | Nessun dato | Nessun dato |
3.7yrs
Durata media
Gestione esperta: FRE's management team is considered experienced (3.7 years average tenure).
Membri del Consiglio di amministrazione
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
Founder | 12.3yrs | AU$351.30k | 16.05% A$ 1.8m | |
Founder | 12.3yrs | AU$290.56k | 15.8% A$ 1.7m | |
Independent Non-Executive Director | 3.8yrs | AU$75.00k | 0.31% A$ 33.6k | |
Non-Executive Director | 2.2yrs | AU$50.00k | Nessun dato |
8.0yrs
Durata media
Consiglio di amministrazione esperto: FRE's board of directors are considered experienced (8 years average tenure).